{"prompt": "['2014-0546', 'August 7, 2017', 'Page 15 of 49', 'Table 1', 'Reference Safety Information (RSI)', 'Summary of Expected Drug-related Treatment-emergent Adverse Events by Preferred Term, Sorted by Frequency, in Studies of Oral Rigosertib', 'Safety-Evaluable (N=337)', 'Rigosertib Integrated Analysis', 'MedDRA Preferred Term [1][2]', 'Any Grade', 'Grade 1', 'Grade 2', 'Grade 3', 'Grade 4', 'Grade 5', 'Bowel movement irregularity', '1 (0.3%)', '1 (0.3%)', '0', '0', '0', '0', 'Leukocyturia', '1 (0.3%)', '1 (0.3%)', '0', '0', '0', '0', 'Liver function test abnormal', '1 (0.3%)', '0', '0', '1 (0.3%)', '0', '0', 'Lymphopenia', '1 (0.3%)', '0', '0', '1 (0.3%)', '0', '0', 'Mental status changes', '1 (0.3%)', '1 (0.3%)', '0', '0', '0', '0', 'Neutropenic sepsis', '1 (0.3%)', '0', '0', '1 (0.3%)', '0', '0', 'Polyuria', '1 (0.3%)', '1 (0.3%)', '0', '0', '0', '0', 'Red blood cells urine', '1 (0.3%)', '0', '1 (0.3%)', '0', '0', '0', 'Red blood cells urine positive', '1 (0.3%)', '0', '1 (0.3%)', '0', '0', '0', 'Urethral pain', '1 (0.3%)', '1 (0.3%)', '0', '0', '0', '0', 'Urge incontinence', '1 (0.3%)', '0', '1 (0.3%)', '0', '0', '0', 'Urine analysis abnormal', '1 (0.3%)', '1 (0.3%)', '0', '0', '0', '0', 'Urine flow decreased', '1 (0.3%)', '1 (0.3%)', '0', '0', '0', '0', 'Urine output decreased', '1 (0.3%)', '1 (0.3%)', '0', '0', '0', '0', 'White blood cells urine positive', '1 (0.3%)', '1 (0.3%)', '0', '0', '0', '0', '[1] Number of Patients used as denominator to calculate percentages.', '[2] Patients with multiple TEAEs were only counted once within a summary category: preferred term, maximum grade, or relationship to treatment. Treatment-Emergent Adverse', 'Events (TEAEs) were defined as all AEs that occurred after the first dose of study medication or within 30 day post-treatment period. MedDRA version 17.0.', 'Studies include 09-01, 09-02, 09-03, 09-04, 09-05, 09-07, 09-08, 09-09 and 09-12.']['2014-0546', 'August 7, 2017', 'Page 16 of 49', 'Based on nonclinical studies, the following effects could potentially be observed:', 'Decrease in spleen or thymus weight;', \"In men, reduction in sperm cell count and/or decrease of testicles' weight that could lead\", 'to infertility, and/or a decrease in the size of the prostate gland; these effects were', 'partially or completely reversible in animals.', 'Fetotoxicity (lower fetal weight) and teratogenicity (increased incidence of primarily', 'craniofacial malformations); no maternal toxicity was observed in animals;', 'Rigosertib was found to be an inhibitor or a substrate of the following transporters, which', 'has the potential to lead to drug-drug interactions. Caution should be exercised and dose', 'adjustments of the concomitant substrate or inhibitor drugs should be considered when', 'dosing concurrently with rigosertib (see list of drugs that are substrates or inhibitors of', 'these transporters at: FDA Guidance DDI).', 'Inhibition of CYP isoform 2C9 in vitro at clinically relevant concentrations.', 'Additional in vitro studies to determine the effect of plasma protein binding', 'showed that, when rigosertib was incubated with cryopreserved human', 'hepatocytes in 100% human plasma to determine its potential for inhibition of', 'CYP2C9, the potency of rigosertib decreased by 2.74-fold (12.5 M) relative to', 'that measured in the absence of protein. Based on these data, rigosertib has the', 'potential for drug-drug interaction (DDI) with CYP2C9;', 'Time-dependent inhibition of CYP isoform 2C8. However, additional in vitro', 'studies to determine the effect of plasma protein binding showed that, in the', 'presence of plasma, the potency of rigosertib to inhibit CYP2C8 was very low', '(IC50 > 300 M). Based on these data, rigosertib does not have the potential for', 'DDI with CYP2C8;', 'Inhibition of OAT3, OATP1B1, and OATP1B3 at clinically relevant', 'concentrations. Rigosertib could impair the excretion of co-medications that are', 'known substrates of these transporters;', 'Rigosertib was found to be a substrate (but not an inhibitor) of P-gp and BCRP.', 'Co-medications that are known inhibitors of these transporters should be taken', 'with caution, as they could impair the hepatic excretion of rigosertib', 'Rigosertib is 98% protein bound and should be administered with caution to', 'patients who are taking concomitant medications that are also highly protein', 'bound (eg, warfarin).', 'There was no evidence of ocular or cutaneous phototoxicity in female pigmented rats', 'after 3 consecutive daily IV administrations of rigosertib with single solar-simulated', 'ultraviolet radiation exposure simultaneously during the final administration.', 'Based on all clinical and nonclinical data available to date, and evaluating the frequency of', 'reported events, the following are considered potential risks: Urinary disorders; Hyponatremia;', 'pulmonary alveolar haemorrhage/respiratory distress; Hepatic effects; Central nervous system']\n\n###\n\n", "completion": "END"}